



\* For background correction, add 100  $\mu$ l of Background Control Mix (without substrate) to sample background control well(s) and mix well.

**4. Measurement:** Start measuring absorbance immediately at 450 nm in a kinetic mode for 10-120 min. at 37°C.

**Note:**

- a) The NADPH Standard Curve can be read in Endpoint mode (after 10 min of incubation).
- b) Sample incubation time depends on the AKR activity in them. We recommend measuring the OD in a kinetic mode, and choosing two time points ( $T_1$  &  $T_2$ ) in the linear range of the standard curve to calculate the AKR activity of the samples.

**5. Calculation:** Subtract 0 Standard reading from all readings. Plot the NADPH Standard Curve. Calculate the AKR activity of the test samples by subtracting the absorbance reading at  $T_2$  and  $T_1$ :  $\Delta OD = A_2 - A_1$ . If necessary subtract the  $\Delta BC = BC_2 - BC_1$  from this reading. Apply the  $\Delta OD$  to the NADPH Standard Curve to get B nmol of NADPH generated during the reaction time ( $\Delta T = T_2 - T_1$ ).

$$\text{Sample Aldo-keto Reductase Activity} = \frac{B}{(\Delta T \times V)} \times D = \text{nmol/min/ml} = \text{mU/ml}$$


Where: **B** = NADPH amount from Standard Curve (nmol).

$\Delta T$  = reaction time (min.).

**V** = sample volume initially added into the reaction well (ml).

**D** = Dilution Factor

**Unit Definition:** One unit of aldo-keto reductase is the amount of enzyme that generates 1.0  $\mu$ mol of NADPH per min. at pH 8.0 at 37°C.



**Figure:** (a) NADPH standard curve; (b) AKR Positive Controls ( $\mu$ /assay). (c) Human tissue samples and cancer cell line (HepG2: hepatocellular carcinoma; MDA-MB: adenocarcinoma; Jurkat: acute T cell leukemia) lysates were homogenized as described in the kit protocol. Serial dilutions were tested to ensure the readings were within the linear range of the Standard Curve. AKR activities (mU/mg) were measured and calculated as in the kit protocol. BioVision's EZDetect™ AKR activity assay kit demonstrated enhanced AKR activities in the liver and liver cancer cell line lysates.

**VIII. RELATED PRODUCTS:**

- NADP/NADPH Quantitation Colorimetric Kit (K347)
- Human Recombinant AKR1C1 (6336)
- Human Recombinant AKR1C3 (6337)
- Human Recombinant AKR1C4 (6338)
- Human Recombinant AKR1B10 (6339)
- Human Recombinant AKR1D1 (7358)
- AKR1C3 Inhibitor I (2403)
- AKR1C3 Inhibitor II (2404)
- AKR1C3 Inhibitor III (2424)
- Jurkat Cell lysate (#2401)

**FOR RESEARCH USE ONLY! Not to be used on humans.**